Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raynaud's phenomenon

F M Wigley1, N A Flavahan

  • 1Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Raynaud's phenomenon, a common issue, may stem from blood flow regulation defects and heightened alpha 2-adrenoceptor sensitivity in scleroderma. Oral prostaglandins show therapeutic promise for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute dilation to alpha(2)-adrenoceptor antagonists uncovers dual constriction and dilation mediated by arterial alpha(2)-adrenoceptors.

British journal of pharmacology·2009
Same author

The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea.

Annals of the rheumatic diseases·2009
Same author

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

The European respiratory journal·2009
Same author

Fatigue: an overlooked determinant of physical function in scleroderma.

Rheumatology (Oxford, England)·2008
Same author

Management of Severe Raynaud's Phenomenon.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha2C-adrenoceptors.

American journal of physiology. Heart and circulatory physiology·2008
Same journal

Rheumatology at the Threshold of Artificial Intelligence.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence Regulation in the United States: Current Landscape and Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

The Role of Artificial Intelligence in Medical Education and Training: Implications for Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Sources of Bias in Clinical Artificial Intelligence and Applications in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Toward Bridging the Gap from Artificial Intelligence in Clinical Research to Clinical Practice in Rheumatology: The Mayo Experience.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Vascular Medicine
  • Rheumatology
  • Dermatology

Background:

  • Raynaud's phenomenon affects 3-5% of the population.
  • It is an early indicator of scleroderma, linked to small vessel vasculopathy.
  • Raynaud's phenomenon is believed to result from impaired regional blood flow regulation.

Purpose of the Study:

  • To investigate the underlying mechanisms of Raynaud's phenomenon in scleroderma.
  • To explore the role of alpha 2-adrenoceptors in scleroderma-related vasoconstriction.
  • To evaluate potential therapeutic strategies for Raynaud's phenomenon.

Main Methods:

  • Review of current literature on Raynaud's phenomenon and scleroderma.
  • Analysis of evidence regarding vascular regulation defects.

Related Experiment Videos

  • Examination of alpha 2-adrenoceptor sensitivity in scleroderma vasculature.

    • Main Results:

    • Raynaud's phenomenon is associated with impaired local blood flow control.
    • Scleroderma patients exhibit significant alpha 2-adrenoceptor-mediated vasoconstriction.
    • Oral prostaglandins demonstrate potential as effective treatments.

    Conclusions:

    • Raynaud's phenomenon in scleroderma is linked to vascular regulatory dysfunction.
    • Alpha 2-adrenoceptor sensitivity plays a key role in the condition's pathophysiology.
    • Oral prostaglandins represent a promising therapeutic avenue.